Skip to content

Breast Cancer Health Center

Font Size

Low- and Moderate-Penetrance Genes Associated With Breast and / or Ovarian Cancer

    Table 8. High-probability Breast Cancer Susceptibility Loci Identified Through Genome-Wide Association Studies

    Putative Gene(s)ChromosomeSNPStudy CitationaOdds Ratio (OR) (95% Confidence Interval [CI])bComments
    ER- = estrogen receptor–negative; ER+ = estrogen receptor–positive; PR- = progesterone receptor–negative; PR+ = progesterone receptor–positive; SNP = single nucleotide polymorphism; triple-negative = ER-/PR-/HER2/neu-.
    a Initial study that demonstrated genome-wide significance for each locus.
    b All associations observed in the general population, unless otherwise indicated; when relevant, if association was also observed inBRCA1orBRCA2mutation carriers, it is indicated.
    c OR for best tagSNP was used[109]as a surrogate for published SNP.
    Intergenic /NOTCH21p11.2rs11249433[89]1.08 (1.02–1.15)[109]Stronger in ER+, low-grade[109]; also inBRCA2[119]
    ERBB22q34rs13393577[120]1.53 (1.37–1.70)[120]Identified in Korean subjects[120]
    Intergenic2q35rs13387042[107]1.21 (1.14–1.29)[109]Stronger in bilateral and lobular[116]; also inBRCA1andBRCA2[121]
    SLC4A7, NEK103p24rs4973768[115]1.16 (1.10–1.24)[109]Also inBRCA2[121]
    MRPS305p12rs10941679[114]1.11c(1.04–1.19)[109]Strongest in PR+, low-grade[122]; also inBRCA2[121]
    TERT-/CLPTM15p15rs10069690[117]1.25 (1.16–1.34)[117]Strongest in triple-negative[117]
    MAP3K1 5q11.2rs889312[106]1.22 (1.14–1.30)[109]Stronger in ER+[109]; also inBRCA2[121]
    RNF1466q22rs2180341[110]1.24 (1.13–1.36)[123]Stronger in Ashkenazi Jews[123]
    ESR16q25.1rs2046210[111]1.15c(1.08–1.22)[109]Also inBRCA1[119]
    TAB26q25.1rs9485372[124]0.90 (0.87–0.92)[124]Identified in Chinese subjects[124]
    Intergenic7q32.3rs2048672[125]1.11 (1.05–1.17)[125]Identified in East Asian subjects[125]
    Intergenic/MYC8q24.21rs13281615[106]1.14 (1.07–1.21)[109]Stronger in ER+[109]
    CDKN2A, CDKN2B9p21rs1011970[109]1.09 (1.04–1.14)[109]Stronger in ER+[109]; also inBRCA2[126]
    Intergenic9q31.2rs865686[127]0.89(0.85–0.92)[127]Also inBRCA2[126]
    ANKRD16, FBXO1810p15.1rs2380205[109]0.94 (0.91–0.98)[109] 
    ZNF365 10q21.2rs10995190[109]0.86 (0.82–0.91)[109]Stronger in ER+ in general population[109]; also inBRCA2[128]
    ZMIZ110q22.3rs704010[109]1.07 (1.03–1.11)[109] 
    FGFR2 10q26.13rs2981582[106]1.43 (1.35–1.53)[109]Strongest for ER+, low-grade[116]; also inBRCA2[121]
    LSP111p15.5rs3817198[106]1.12 (1.05–1.19)[109]Also inBRCA2[121]
    Intergenic11q13rs614367[109]1.15 (1.10–1.20)[109]Restricted to ER+ tumors; strongest for ER+/PR+[109]
    BARX211q24.3rs7107217[124]1.08 (1.05–1.11)[124]Identified in Chinese subjects[124]
    PTHLH12p11rs10771399[129]0.85 (0.83–0.88)[129]Also inBRCA1[126]
    Intergenic12q24rs1292011[129]0.92 (0.91–0.94)[129]Restricted to ER+[129]; also inBRCA2[126]
    RAD51B14q24.1rs999737[89]0.89 (0.83–0.95)[109]Associated with all subtypes, including triple-negative[90]; also inBRCA2[126]
    TOX316q12.1rs3803662[106]1.30 (1.22–1.39)[109]Stronger in ER+[116]; also inBRCA1andBRCA2[121]
    BABAM119p13.1rs8170[118]1.26 (1.17–1.35)[130]Restricted to triple-negative in general population[118]; also inBRCA1[130]
    NRIP121q21rs2823093[129]0.94 (0.92–0.96)[129]Restricted to ER+[129]

    Today on WebMD

    Breast Cancer Overview
    From self-exams and biopsies to reconstruction, we’ve got you covered.
    Dealing with breast cancer
    Get answers to your questions.
    woman having mammogram
    Experts don’t agree on all fronts, but you can be your own advocate.
    woman undergoing breast cancer test
    Many women worry. But the truth? Most abnormalities aren’t breast cancer.
    Breast Cancer Treatments Improving
    Resolved To Quit Smoking
    Woman getting mammogram
    Screening Tests for Women
    ovarian cancer overview slideshow
    serious woman
    what is your cancer risk
    10 Ways to Revitalize Slideshow